Tromp A, Hooymans J M, Barendsen B C, van Doormaal J J
Department of Ophthalmology, University Hospital, Groningen, The Netherlands.
Doc Ophthalmol. 1991;78(3-4):153-9. doi: 10.1007/BF00165675.
The polyol pathway has long been associated with diabetic retinopathy. Glucose is converted to sorbitol with the aid of the enzyme aldose reductase. Aldose reductase inhibitors can prevent changes induced by diabetes. A total of 30 patients with minimal background retinopathy were randomly divided into a ponalrestat-taking group and a placebo-taking group. All were followed for 6 months and twenty-three were followed for 12 months. The baseline microaneurysm count was 2.6 +/- 1.9 (mean +/- SD) for the ponalrestat group and 3.5 +/- 2.9 for the placebo group. At 6 months the counts were 3.1 +/- 3.5 and 2.9 +/- 3.6 and after 12 months 3.0 +/- 4.1 and 2.9 +/- 3.4. There is no statistically significant difference between the groups at 0, 6 or 12 months of study. The change in retinopathy severity level did not significantly differ between the two groups at either 6 or 12 months. Ponalrestat administration at a dosage of 600 mg daily for 12 months has no significant effect on the course of minimal retinopathy in diabetic patients.
多元醇途径长期以来一直与糖尿病视网膜病变相关。在醛糖还原酶的作用下，葡萄糖被转化为山梨醇。醛糖还原酶抑制剂可以预防糖尿病引起的变化。总共30例轻度背景性视网膜病变患者被随机分为服用泊那司他组和服用安慰剂组。所有患者均随访6个月，其中23例随访12个月。泊那司他组的基线微动脉瘤计数为2.6±1.9（均值±标准差），安慰剂组为3.5±2.9。6个月时，计数分别为3.1±3.5和2.9±3.6，12个月后分别为3.0±4.1和2.9±3.4。在研究的0、6或12个月时，两组之间无统计学显著差异。在6个月或12个月时，两组视网膜病变严重程度水平的变化均无显著差异。每日服用600 mg泊那司他12个月对糖尿病患者轻度视网膜病变的病程无显著影响。
